← Back to Screener
TriSalus Life Sciences, Inc. Warrant (TLSIW)
Price$0.67
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-82.53%
Price vs S&P 500 (4W)-43.68%
VGM Score6.05
All Metrics
Price vs S&P 500 (YTD)-70.79%
10-Day Avg Trading Volume0.01M
3-Month Avg Trading Volume0.00M
52-Week High$5.00
26-Week Price Return-66.59%
13-Week Price Return-51.94%
3-Month Return Std Dev225.99%
Year-to-Date Return-59.75%
5-Day Price Return-21.40%
Month-to-Date Return-32.51%
Price vs S&P 500 (13W)-61.68%
Beta1.72x
52-Week Low$0.44
mGradeF
vgmGradeF
Show chart for
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TLSIWTriSalus Life Sciences, Inc. Warrant | — | — | F | $0.67 |
| SYKStryker Corporation | C | C | D | $299.46 |
| MMM3M Company | C | F | C | $150.93 |
| BSXBoston Scientific Corp. | C | B | F | $47.98 |
| MDLNMedline Inc. Class A common stock | C | D | D | $35.75 |
| BDXBecton, Dickinson and Co. | B | C | C | $145.33 |
| DXCMDexCom, Inc. | C | B | C | $74.87 |
| RMDResMed Inc. | B | B | D | $186.44 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $316.30 |
| SOLVSolventum Corporation | C | D | C | $75.84 |
| PENPenumbra, Inc. | F | C | C | $318.95 |
About
TriSalus Life Sciences develops drug delivery systems and immune-oncology therapeutics targeting difficult-to-treat liver and pancreatic cancers. The company markets PEDD (Pressure Enabled Drug Delivery) infusion systems, including its latest TriNav device with SmartValve technology, which are in clinical use today. It is also advancing nelitolimod (SD-101), an investigational agent designed to enhance immune response against hepatocellular carcinoma, pancreatic cancer, and other liver tumors.